Amr Abdin, Christian-H Heeger, Kivanc Yalin, Francesco Santoro, Natale Daniele Brunetti, Thomas Fink, Spyridon Liosis, Ben Brueggemann, Ahmad Keelani, Huong Lan Phan, Makoto Sano, Vanessa Sciacca, Evgeny Lyan, Dong A N, Roza Meyer-Saraei, Feifan Ouyang, Karl-Heinz Kuck, Charlotte Eitel, Julia Vogler, Roland Richard Tilz
University Heart Center Luebeck, Medical Clinic II (Department of Cardiology, Angiology and Intensive Care Medicine), University Hospital Schleswig-Holstein, Luebeck, Germany.
Current affiliation: University Hospital RWTH Aachen, Department of Cardiology, Angiology and Critical Care (Medical Clinic 1), Aachen, Germany.
J Atr Fibrillation. 2020 Apr 30;12(6):2285. doi: 10.4022/jafib.2285. eCollection 2020 Apr-May.
Cryoballoon based catheter ablation (CB-CA) is an established therapy for treatment of symptomatic atrial fibrillation (AF). However, data about AF ablation using the CB in the diabetic population is sparse. The aim of this single center retrospective study is to evaluate the safety and efficacy of CB ablation in patients with diabetes mellitus (DM) as compared to patients without DM.
Between July 2015 and December 2017, 397 consecutive patients underwent CB-CA for AF. Forty-eight consecutive patients with DM (DM group, study group) were compared with propensity score-matched patients without DM (n=48, control group). All patients underwent pulmonary vein isolation (PVI) using the second-generation CB (CB2). The mean age in the DM group was 66.9±9.5 years and 69.5±8.8 in the non-DM group (p=0.18). During a follow-up of 12.7±5.1 months, single procedure success rate for the DM and the non-DM group was 68.7% and 70.8%, respectively (p=0.82). The most common complication was transient phrenic nerve palsy (4 DM group vs. 0 non-DM group, p=0.04). No severe complication such as procedure related deaths, atrio-esophageal fistula or cerebrovascular embolic events occurred.
Our data strengthen the value of CB2 based ablation for the treatment of AF as an effective and safe procedure in DM patients, with similar success rates when compared with a non-DM population.
基于冷冻球囊的导管消融术（CB-CA）是治疗症状性心房颤动（AF）的既定疗法。然而，关于在糖尿病患者中使用冷冻球囊进行房颤消融的数据很少。这项单中心回顾性研究的目的是评估与非糖尿病患者相比，糖尿病（DM）患者进行冷冻球囊消融的安全性和有效性。
2015年7月至2017年12月期间，397例连续患者接受了CB-CA治疗房颤。将48例连续的糖尿病患者（DM组，研究组）与倾向评分匹配的非糖尿病患者（n = 48，对照组）进行比较。所有患者均使用第二代冷冻球囊（CB2）进行肺静脉隔离（PVI）。DM组的平均年龄为66.9±9.5岁，非DM组为69.5±8.8岁（p = 0.18）。在12.7±5.1个月的随访期间，DM组和非DM组的单次手术成功率分别为68.7%和70.8%（p = 0.82）。最常见的并发症是短暂性膈神经麻痹（DM组4例 vs. 非DM组0例，p = 0.04）。未发生与手术相关的死亡、心房食管瘘或脑血管栓塞事件等严重并发症。
我们的数据强化了基于CB2的消融术在治疗房颤方面的价值，对于DM患者是一种有效且安全的手术，与非DM人群相比成功率相似。
